- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02139930
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Mayo Clinic
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33617
- Moffitt Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Johns Hopkins University
-
-
Minnesota
-
Duluth, Minnesota, Estados Unidos, 55812
- University of Minnesota Medical School Duluth
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97403
- Oregon Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- MDAnderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18+
- Daily smokers who smoke an average of at least five cigarettes per day for at least 1 year
- Breath CO levels > 8 ppm (if ≤ 8 ppm, then NicAlert Strip level must indicate regular smoking)
Exclusion Criteria:
- Planned quit date in the next 30 days
- Currently seeking treatment for smoking cessation
- Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (non-cessation intermittent use acceptable)
- A quit attempt in the past 30 days resulting in greater than 3 days of abstinence
- Using other tobacco products or e-cigarettes more than 9 days in the past 30 days
- Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)
- Unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)
- Schizophrenia and schizoaffective disorder
- Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms.
Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP
- Marijuana will be tested for but will not be an exclusionary criterion.
- Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.
- Participants failing the toxicology screen will be allowed to re-screen once.
Blood alcohol level > 0.01
a. Participants failing the blood alcohol screen will be allowed to re-screen once.
- Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day (female/male))
- Pregnant, trying to become pregnant or breastfeeding
- Predominant use of 'roll your own cigarettes'
- CO reading >80 ppm
Systolic BP greater than or equal to 160
a. Participants failing for blood pressure will be allowed to re-screen once.
Diastolic BP greater than or equal to 100
a. Participants failing for blood pressure will be allowed to re-screen once.
Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
Heart rate greater than or equal to 105 bpm
a. Participants failing for heart rate will be allowed to re-screen once.
Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for heart rate will be allowed to re-screen once.
- Indicating any suicidal ideation in the past month, suicide attempts in the past 5 years (if within past 5 to 10 years, requires physician approval), or score of >4 on the MINI suicide subscale
- Household member enrolled in the study concurrently.
- Inability to independently read and comprehend the consent form and other written study materials and measures because participants are required to complete parts of the protocol at home independently.
- Participated in prior study that involved reduced nicotine content cigarettes.
- Having participated in a research study during the past three months in a study that would impact baseline smoking or response to study products.
Currently taking the following anticonvulsant medications:
- Phenytoin [Brand Name: Dilantin]
- Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol]
- Oxcarbazepine [Brand Name: Trileptal]
- Primidone [Brand Name: Mysoline]
- Phenobarbital
Currently taking the following medication:
- Bendamustine (Treanda)
- Clopidogrel (Plavix)
- Clozapine (Clozaril, FazaClo)
- Erlotinib (Tarceva)
- Flecainide (Tambocor)
- Fluvoxamine (Luvox)
- Irinotecan (Camptosar)
- Olanzapine (Zyprexa)
- Ropinirole (Requip)
- Tacrine (Cognex)
- Theophylline (Theo Dur, etc.)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Normal Nicotine Control Group
These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
|
Experimental: Immediate Nicotine Reduction Group
This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes.
They will smoke these cigarettes for 20 weeks.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
|
Experimental: Gradual Nicotine Reduction Group
This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
|
Participants will smoke experimental cigarettes for a period of 20-weeks.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Toxicant exposure pattern: Expired air carbon monoxide
Periodo de tiempo: 20-week treatment period
|
Between group comparison of expired air carbon monoxide (CO) values at week 20 using baseline CO values as a covariate.
|
20-week treatment period
|
|
Toxicant exposure pattern: Urinary phenanthrene tetroal (Phe)
Periodo de tiempo: 20-week treatment period
|
Between group comparison of urinary phenanthrene tetroal values at week 20 using baseline values as a covariate.
|
20-week treatment period
|
|
Toxicant exposure pattern: Urinary mercapturic acids of acrolein
Periodo de tiempo: 20-week treatment period
|
Between group comparison of urinary mercapturic acid level at week 20 using baseline values as a covariate.
|
20-week treatment period
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Nicotine exposure: Total nicotine equivalents (TNE)
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Other toxicant exposure: Tobacco specific nitrosamines-Total NNAL and NNN
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of urinary total NNAL and NNN levels at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Effect biomarker: C-Reactive protein-high sensitivity as an inflammation biomarker
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of C-Reactive protein levels in serum at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Measure of acceptability: Retention in study
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of early termination from the study.
|
End of treatment (Week 20)
|
|
Measure of acceptability: Non-compliance
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of use of non-study tobacco products.
|
End of treatment (Week 20)
|
|
Effect biomarker: 8-epi-PGF2α as a biomarker for oxidative stress
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of 8-epi-PGF2α at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Effect biomarker: White blood cells count as inflammation biomarker
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of white blood cell count at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
|
Nicotine exposure: Urinary cotinine
Periodo de tiempo: End of treatment (Week 20)
|
Between group comparison of urinary total nicotine equivalents at week 20 using baseline values as a covariate.
|
End of treatment (Week 20)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Eric Donny, PhD, University of Pittsburgh
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos inducidos químicamente
- Trastornos relacionados con sustancias
- Trastorno por consumo de tabaco
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Agentes colinérgicos
- Estimulantes ganglionares
- Agonistas nicotínicos
- Agonistas colinérgicos
- Nicotina
Otros números de identificación del estudio
- U54 DA031659-P2
- U54DA031659 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .